Gut Microbiota Composition Is Related to AD Pathology

Barbara J H Verhaar1,2,3, Heleen M A Hendriksen3, Francisca A de Leeuw3

  • 1Department of Internal Medicine - Geriatrics, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center (UMC), Amsterdam, Netherlands.

Frontiers in Immunology
|February 17, 2022
PubMed
Abstract

Insights

Gut bacteria composition links to Alzheimer's disease (AD) biomarkers. Lower levels of short-chain fatty acid (SCFA)-producing microbes correlate with higher odds of amyloid and phosphorylated tau positivity in AD patients.

Area of Science:

  • Microbiome research
  • Neurodegenerative disease biomarkers
  • Machine learning in medicine

Background:

  • Inconsistent findings exist regarding gut microbiota alterations in Alzheimer's disease (AD).
  • Investigating the link between gut microbiome and AD biomarkers is crucial for understanding disease mechanisms.

Purpose of the Study:

  • To explore associations between gut microbiota composition and AD biomarkers (amyloid and p-tau).
  • To utilize machine learning models to identify microbial signatures related to AD pathology in patients with AD dementia, mild cognitive impairment (MCI), and subjective cognitive decline (SCD).

Main Methods:

  • 170 participants (AD dementia, MCI, SCD) from the Amsterdam Dementia Cohort.
  • 16S rRNA sequencing for gut microbiome analysis.
  • Machine learning classification models to assess associations between microbiota and CSF amyloid-beta 1-42, p-tau, and MRI visual scores.

Main Results:

  • Machine learning models achieved AUCs of 0.64 for amyloid and 0.63 for p-tau prediction from microbiota.
  • Specific microbes, including SCFA-producing species, were significantly associated with amyloid and p-tau positivity.
  • Lower abundance of SCFA-producing microbes like *Lachnospiraceae* spp. and *Roseburia hominis* was linked to increased odds of amyloid and p-tau positivity.

Conclusions:

  • Gut microbiota composition is significantly associated with amyloid and p-tau status in individuals with cognitive decline.
  • Reduced abundance of SCFA-producing microbes may increase the risk or indicate the presence of AD pathology.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
713
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
279
Anatomy of the Intestines01:23

Anatomy of the Intestines

Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
83.9K